Longeveron Inc. will report Q1 2025 financial results and host a conference call on May 8, 2025.
Quiver AI Summary
Longeveron Inc., a clinical stage biotechnology company focused on regenerative medicine, announced it will release its first quarter 2025 financial results and a business update on May 8, 2025, after U.S. market close, followed by a conference call at 4:30 p.m. ET. The company is developing laromestrocel (Lomecel-B™), a stem cell therapy from young adult donors, aimed at treating serious aging-related conditions, including hypoplastic left heart syndrome, Alzheimer’s disease, and aging-related frailty. Laromestrocel has received multiple FDA designations, highlighting its significance in addressing unmet medical needs. An archived replay of the conference will be available on the company's website.
Potential Positives
- Longeveron Inc. is set to report first quarter 2025 financial results and provide a business update, indicating transparency and engagement with stakeholders.
- The company’s lead investigational product, laromestrocel, has received multiple FDA designations, highlighting its potential in addressing serious medical conditions and enhancing investor confidence.
- The upcoming conference call and webcast provide opportunities for real-time interaction with investors, showcasing the company's commitment to keeping stakeholders informed.
Potential Negatives
- The announcement of financial results in a few days may indicate challenges in performance or growth, as companies typically prefer to highlight positive financial metrics proactively.
- The focus on multiple FDA designations may signal a lack of clarity or confidence regarding the primary efficacy and safety of their lead product, as companies often tout successful trials instead.
- The press release does not provide any financial guidance or insights into expected performance, which could lead to uncertainty among investors about the company's future prospects.
FAQ
When will Longeveron announce its Q1 2025 financial results?
Longeveron will announce its first quarter 2025 financial results on May 8, 2025.
What time will the Longeveron conference call start?
The Longeveron conference call will begin at 4:30 p.m. ET on May 8, 2025.
How can I access the Longeveron conference call and webcast?
You can access the conference call at 1.877.407.0789 with Conference ID: 13752361, or via the webcast link.
What is Longeveron's main product?
Longeveron's main investigational product is laromestrocel (Lomecel-B™), a mesenchymal stem cell therapy.
What FDA designations has Longeveron received for its programs?
Longeveron has received Orphan Drug, Fast Track, and RMAT designations for its various pipeline programs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LGVN Insider Trading Activity
$LGVN insiders have traded $LGVN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $LGVN stock by insiders over the last 6 months:
- KHOSO BALUCH sold 1,250 shares for an estimated $2,588
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LGVN Hedge Fund Activity
We have seen 12 institutional investors add shares of $LGVN stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 99,288 shares (+220.7%) to their portfolio in Q4 2024, for an estimated $171,768
- VIRTU FINANCIAL LLC added 30,402 shares (+inf%) to their portfolio in Q4 2024, for an estimated $52,595
- STATE STREET CORP added 30,200 shares (+198.9%) to their portfolio in Q4 2024, for an estimated $52,246
- JANE STREET GROUP, LLC added 20,493 shares (+inf%) to their portfolio in Q4 2024, for an estimated $35,452
- NORTHERN TRUST CORP added 18,190 shares (+inf%) to their portfolio in Q4 2024, for an estimated $31,468
- COMMONWEALTH EQUITY SERVICES, LLC added 12,455 shares (+inf%) to their portfolio in Q4 2024, for an estimated $21,547
- HRT FINANCIAL LP added 11,681 shares (+inf%) to their portfolio in Q4 2024, for an estimated $20,208
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.
| Conference Call and Webcast Details: | |||
| Conference Call Number: | 1.877.407.0789 | ||
| Conference ID: | 13752361 | ||
| Call me TM Feature: | Click Here | ||
| Webcast: | Click Here | ||
An archived replay of the webcast will be available on the “ Events & Presentations ” section of the Company’s website following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn , X , and Instagram .
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
[email protected]
